Approval triggers $10m milestone payment to Sosei
Seebri® Breezhaler® 44 mcg delivered dose approved for maintenance treatment of COPD will be
available to patients and physicians in some EU markets by year-end
In GLOW trials, Seebri® Breezhaler® improved lung function, reduced shortness of breath, reduced
exacerbations, and improved quality of life up to 52 weeks versus
GLOW2 study showed Seebri® Breezhaler® provided 24-hour bronchodilation and is superior to placebo and similar
to open-label tiotropium in improving lung function
TOKYO, Oct. 1, 2012 /CNW/ - Sosei Group Corporation ("Sosei"; TSE
Mothers Index: 4565) confirms the information released today by
Novartis that the European Commission has approved Seebri® Breezhaler® (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg
glycopyrronium measured dose per capsule), as a once-daily inhaled
maintenance bronchodilator treatment to relieve symptoms in adult
patients with chronic obstructive pulmonary disease (COPD). This
approval triggers a $10m milestone payment to Sosei.
The European Commission approved Seebri® Breezhaler® based on data from the Novartis Phase III GLOW trials which
demonstrated the safety and efficacy of glycopyrronium 44 mcg and
involved 1,996 COPD patients who required maintenance treatment from
around the world, with many in EU countries,,.
The GLOW trials showed that glycopyrronium, when compared to placebo,
significantly improved lung function over the first four hours after
morning dosing and that this benefit was sustained for 24 hours over a
52-week period. Patients on glycopyrronium demonstrated improved lung function,
reduced shortness of breath, reduced exacerbations, reduced use of
rescue medication, improved quality of life and improved exercise
tolerance compared to placebo,,.
GLOW1 was a 26-week, randomized, double-blind, placebo-controlled study.
The study demonstrated the clinically significant superiority of
glycopyrronium versus placebo for lung function improvements at 12
weeks (primary endpoint) measured by trough FEV1 (p0.01).
GLOW2 demonstrated a similar magnitude of effect and also showed that
glycopyrronium was similar to open-label (OL) tiotropium over 52 weeks
measured by improvements in trough FEV1 compared to placebo. In addition to demonstrating benefits in terms of
lung function, glycopyrronium exhibited a rapid onset of action within
five minutes at first dose and reduced exacerbations. Significant
benefits in both breathlessness and health-related quality of life
(HRQL), as measured by the Transition Dyspnea Index (TDI) and St.
George's Respiratory Questionnaire (SGRQ) compared to placebo, were
also demonstrated. GLOW2 was a 52-week, randomized, double-blind,
placebo-controlled study with OL tiotropium 18 mcg as an active
The GLOW3 study showed that after glycopyrronium was administered in the
morning, patients experienced improved exercise tolerance from the
first dose onward. Overall, patients treated with glycopyrronium
experienced a significant 21% improvement in exercise endurance versus
placebo at the end of the study (day 21), with a significant 10%
increase from day one (both p0.001). In all studies, glycopyrronium was
shown to have an overall safety profile similar to placebo.
CEO of Sosei, Shinichi Tamura commented:
"We are delighted with the EU approval of Seebri Breezhaler which marks
an important milestone in the evolution of the Sosei business. The latest Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines recommend long-acting muscarinic antagonists as first-line
therapy for a broad range of COPD patients with moderate to very severe
symptoms. Seebri Breezhaler will provide an important once-daily
treatment option for this serious disease".
Notes for editors
About Seebri® Breezhaler®:
Seebri® Breezhaler® (glycopyrronium bromide) is a long-acting muscarinic antagonist (LAMA)
developed as a once-daily inhaled maintenance therapy for the treatment
of COPD. Glycopyrronium bromide was exclusively licensed to Novartis in
April 2005 by Sosei and its co-development partner Vectura. Phase III
data from the GLOW 1, 2 and 3 studies demonstrated that glycopyrronium
increased patients' lung function over a 24-hour period compared to
placebo with a fast onset of action at first dose, and improved
exercise endurance versus placebo,,. Seebri® also received MHLW approval as once-daily maintenance treatment for
COPD in Japan on 28 September 2012, under the brand name Seebri® Inhalation Capsules 50mcg. The US filing for Seebri® Breezhaler® is expected in 2014.
QVA149 is an investigational inhaled, once-daily, fixed-dose combination
of indacaterol maleate and glycopyrronium bromide. QVA149 is being
investigated for the maintenance treatment of COPD in the Phase III
IGNITE clinical trial program. IGNITE is one of the largest
international clinical trial programs in COPD comprising 10 studies in
total with more than 7,000 patients across 42 countries-. The first five studies (ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK)
have already completed in 2012 with three additional studies (BLAZE,
ARISE, BEACON) expected to complete by the end of the year. The studies
are designed to investigate efficacy, safety and tolerability, lung
function, exercise endurance, exacerbations, breathlessness and quality
of life. Initial filings for regulatory approval are expected in Q4
2012 for Europe and Japan. US filing is expected at the end of 2014.
All Novartis inhaled COPD portfolio products are being developed for
delivery via the Breezhaler® device, a single-dose dry powder inhaler (SDDPI), which has low air
flow resistance, making it suitable for patients with airflow
limitation, such as COPD patients. The Breezhaler® device allows patients to hear, feel and see that they have taken the
COPD is a progressive disease associated mainly with tobacco smoking,
air pollution or occupational exposure, which can cause obstruction of
airflow in the lungs resulting in debilitating bouts of breathlessness.
It affects an estimated 210 million people worldwideand is predicted to be the third leading cause of death by 2020. Although COPD is often thought of as a disease of the elderly, 50% of
patients are estimated to be within the ages of 50 and 65, which means
that half of the COPD population are likely to be impacted at the peak
of their earning power and family responsibilities.
Sosei is an international biopharmaceutical company anchored in Japan
with a global reach. It practises a reduced risk business model by
acquiring compounds from, and bringing compounds into, Japan through
exploitation of its unique position within global markets.
For further information about Sosei, please visit http://www.sosei.com.
This press release contains forward-looking statements, including
statements about the discovery, development and commercialisation of
products. Various risks may cause Sosei's actual results to differ
materially from those expressed or implied by the forward-looking
statements, including: adverse results in clinical development
programmes; failure to obtain patent protection for inventions;
commercial limitations imposed by patents owned or controlled by third
parties; dependence upon strategic alliance partners to develop and commercialise
products and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from development
efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors. As a result of these factors, prospective
investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.
D'Urzo A, et al. Efficacy and safety of once-daily NVA237 in patients with
moderate-to-severe COPD: the GLOW1 trial. Respiratory Research 2011, 12:156.
Kerwin E, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients
with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Resp J. 2012. Published on July 26, 2012 (doi:10.1183/09031936.00040712). Last
accessed 12 September 2012.
Beeh K, Drollmann A, Di Scala L, Smith R. Once-daily NVA237 improves
exercise endurance from first dose in patients with COPD: the GLOW3
trial. Int J Chron Obstruct Pulmon Dis. 2012; 7:503-513.
Onbrez® Breezhaler® (indacaterol) EU Summary of Product Characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001114/human_med_001219.jsp&mid=WC0b01ac058001d124. Last Accessed 12 September 2012.
ClinicalTrials.gov. A Study to Assess the Efficacy, Safety and
Tolerability of Once-daily QVA149 in Patients With Moderate to Severe
Chronic Obstructive Pulmonary Disease (COPD) (SHINE). NCT01202188. http://www.clinicaltrials.gov/ct2/show/NCT01202188?term=NCT01202188&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. QVA149 versus Fluticasone/Salmeterol in Patients
With Chronic Obstructive Pulmonary Disease (COPD) (ILLUMINATE).
NCT01315249 http://www.clinicaltrials.gov/ct2/show/NCT01315249?term=NCT01315249&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. A Study to Assess the Long-term Safety of QVA149
(ENLIGHTEN). NCT01120717 http://www.clinicaltrials.gov/ct2/show/NCT01120717?term=QVA149+ENLIGHTEN&rank=1. Last accessed 12 September 2012
ClinicalTrials.gov. Effect of QVA149 on Exercise Tolerance in Patients
With Chronic Obstructive Pulmonary Disease (COPD) (BRIGHT).
NCT01294787. http://www.clinicaltrials.gov/ct2/show/NCT01294787?term=NCT01294787.&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. Effect of QVA149 Versus NVA237 and Tiotropium on
Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK).
NCT01120691. http://www.clinicaltrials.gov/ct2/show/NCT01120691?term=NCT01120691.&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. Long Term Safety and Tolerability of QVA149 Versus
Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary
Disease (COPD) (ARISE). NCT01285492. http://www.clinicaltrials.gov/ct2/show/NCT01285492?term=NCT01285492.&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. The Effect of QVA149 on Dyspnea in Patients With
Chronic Obstructive Pulmonary Disease (COPD) (BLAZE). NCT01490125. http://www.clinicaltrials.gov/ct2/show/NCT01490125?term=NCT01490125.&rank=1. Last accessed 12 September 2012
ClinicalTrials.gov. Comparison of Safety and Efficacy of the Combination
Product QVA149A Against the Concurrent Administration of the Individual
Components, QAB149 and NVA237, in Patients With Chronic Obstructive
Pulmonary Disease (COPD) (BEACON). http://www.clinicaltrials.gov/ct2/show/NCT01529632?term=BEACON&rank=6. Last accessed 12 September 2012.
ClinicalTrials.gov. Comparison of Long-term Safety of the Combination
Product QVA149A Against Placebo and Standard of Care Treatment in
Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe
Airflow Limitation (GLISTEN). http://www.clinicaltrials.gov/ct2/show/NCT01610037?term=GLISTEN&rank=1. Last accessed 12 September 2012.
ClinicalTrials.gov. The Effect of QVA149 on Health Related Quality of
Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
(QUANTIFY). http://clinicaltrials.gov/ct2/show/NCT01574651?term=QUANTIFY&rank=1. Last accessed 12 September 2012.
FDA Access Data. Spiriva Medical Review Part 2, pages 37-38.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-395_Spiriva.cfm. Last accessed 12 September 2012.
FDA Access Data. Advair Medical Review Nov. 17, 2003, Page 133. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021077_S003_ADVAIR_DISKUS.pdf Last accessed 12 September 2012.
Global Alliance Against Chronic Respiratory Diseases (GARD). Global
surveillance, prevention and control of chronic respiratory diseases: a
comprehensive approach. Available at: http://www.who.int/gard/publications/GARD%20Book%202007.pdf Last accessed 12 September 2012.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
Strategy for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease. Updated 2011.
Fletcher MJ et al., COPD Uncovered: An International survey on the impact of chronic
obstructive pulmonary disease (COPD) on a working age population. BMC Public Health 2011;11:612.
SOURCE: Sosei Group Corporation
For further information:
Enquiries: Sosei Group Corporation, Tokyo Office, Milica STOJKOVIC, Investor Relations, +81(0)3-5210-3399, email@example.com; London Office, Kathryn LYDON, PA to CEO & Corporate Communication, +44(0)20-7691-0983, firstname.lastname@example.org